Elevated COX-2 Expression in Cervical Carcinoma
- 1 October 2001
- journal article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 24 (5) , 443-446
- https://doi.org/10.1097/00000421-200110000-00006
Abstract
The purpose of this study was to correlate the level of cyclooxygenase-2 (COX-2) expression in carcinoma of the cervix with the clinical endpoints: local control, cause-specific survival, and patterns of failure in patients treated with radiotherapy. Formalin-fixed, paraffin-embedded tumor biopsies were stained for COX-2. Clinical factors such as stage, grade, tumor size, pre- and posttreatment hemoglobin level, and radiotherapy dose were also evaluated. Actuarial local control rates and cause-specific survival were determined according to the Kaplan-Meier method. COX-2 distribution staining was the only prognostic factor that was associated with local control and cause-specific survival. High COX-2 distribution staining was associated with decreased local control and decreased cause-specific survival by log rank comparison of Kaplan-Meier survival curves. The 5-year cause-specific survival rates for tumors with low versus high COX-2 distribution values were 90% and 22%, respectively (p = 0.0003). Actuarial pelvic control at 5 years was superior in patients with low COX-2 distribution staining (92%) compared with high staining (42%, p = 0.005). COX-2 staining intensity was found to correlate positively with tumor size (p = 0.02). These findings indicate that increased expression of COX-2 yields reduced pelvic control and cause-specific survival in patients with invasive carcinoma of the cervix treated with radiotherapy. Previously, inhibition of COX-2 has been demonstrated to sensitize tumors to radiation without effect on normal tissue. Taken together, these data may support a novel therapeutic application of COX-2 inhibitors in the treatment of carcinoma of the cervix.Keywords
This publication has 11 references indexed in Scilit:
- Breast cancer after mantle irradiation for Hodgkin’s disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2International Journal of Radiation Oncology*Biology*Physics, 2001
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- COX-2 is expressed in human pulmonary, colonic, and mammary tumorsCancer, 2000
- Expression of p27 and p53 in cervical squamous cell carcinoma patients treated with radiotherapy aloneCancer, 2000
- Host cyclooxygenase-2 modulates carcinoma growthJournal of Clinical Investigation, 2000
- High Cyclooxygenase-2 Expression in Stage IB Cervical Cancer with Lymph Node Metastasis or Parametrial InvasionGynecologic Oncology, 2000
- Enhancement of Tumor Response to -Radiation by an Inhibitor of Cyclooxygenase-2 EnzymeJNCI Journal of the National Cancer Institute, 1999
- Interstitial fluid pressure in cervical carcinomaCancer, 1998
- Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potentialProceedings of the National Academy of Sciences, 1997
- Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2Cell, 1995